Tonix制药公司报告损失惨重, 但其股票激增, Tonix Pharmaceuticals reports a big loss but its stock surges, getting a "sell" rating despite the gain.

Tonix制药公司(TNXP)报告每季度每股损失9.77美元,损失的分析师估计数为3.54美元。 Tonix Pharmaceuticals (TNXP) reported a quarterly loss of $9.77 per share, missing analyst estimates by $3.54. 尽管损失了,该公司的股票在放行日上扬了4.25美元,交易量为255万股。 Despite the loss, the company's stock rose $4.25 on the release day, with trading volume at 2.55 million shares. StockNews.com以“销售”评级开始报导。 StockNews.com initiated coverage with a "sell" rating. 2025年3月14日,库存量又增加了18.55%,接近19.30美元,可能是因为审判结果良好,尽管这一点没有得到证实。 The stock experienced a further 18.55% increase on March 14, 2025, closing at $19.30, likely due to positive trial results, though this was not confirmed.